vs

Side-by-side financial comparison of CTO Realty Growth, Inc. (CTO) and Health Catalyst, Inc. (HCAT). Click either name above to swap in a different company.

Health Catalyst, Inc. is the larger business by last-quarter revenue ($74.7M vs $41.2M, roughly 1.8× CTO Realty Growth, Inc.). CTO Realty Growth, Inc. runs the higher net margin — 15.1% vs -121.9%, a 137.0% gap on every dollar of revenue. On growth, CTO Realty Growth, Inc. posted the faster year-over-year revenue change (15.0% vs -6.2%). Over the past eight quarters, CTO Realty Growth, Inc.'s revenue compounded faster (19.5% CAGR vs -0.0%).

Keller Williams Realty is an American technology and international real estate franchise with headquarters in Austin, Texas. It is the largest real estate franchise in the United States by sales volume as of 2022.

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company based in Coral Gables, Florida, United States. The company develops medicines for rare diseases, including the phosphate salt of amifampridine for the treatment of Lambert–Eaton myasthenic syndrome (LEMS). The drug is referred to under the trade name Firdapse, which was approved by the FDA for approved use in children 6 years and older with LEMS in addition to the prior approval for use in adults with LEMS on November 28, 2018. Fir...

CTO vs HCAT — Head-to-Head

Bigger by revenue
HCAT
HCAT
1.8× larger
HCAT
$74.7M
$41.2M
CTO
Growing faster (revenue YoY)
CTO
CTO
+21.2% gap
CTO
15.0%
-6.2%
HCAT
Higher net margin
CTO
CTO
137.0% more per $
CTO
15.1%
-121.9%
HCAT
Faster 2-yr revenue CAGR
CTO
CTO
Annualised
CTO
19.5%
-0.0%
HCAT

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
CTO
CTO
HCAT
HCAT
Revenue
$41.2M
$74.7M
Net Profit
$6.2M
$-91.0M
Gross Margin
Operating Margin
175.0%
-115.3%
Net Margin
15.1%
-121.9%
Revenue YoY
15.0%
-6.2%
Net Profit YoY
174.4%
-340.3%
EPS (diluted)
$0.13
$-1.29

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CTO
CTO
HCAT
HCAT
Q1 26
$41.2M
Q4 25
$38.3M
$74.7M
Q3 25
$37.8M
$76.3M
Q2 25
$37.6M
$80.7M
Q1 25
$35.8M
$79.4M
Q4 24
$35.7M
$79.6M
Q3 24
$31.8M
$76.4M
Q2 24
$28.8M
$75.9M
Net Profit
CTO
CTO
HCAT
HCAT
Q1 26
$6.2M
Q4 25
$28.3M
$-91.0M
Q3 25
$2.9M
$-22.2M
Q2 25
$-23.4M
$-41.0M
Q1 25
$2.3M
$-23.7M
Q4 24
$-15.2M
$-20.7M
Q3 24
$6.2M
$-14.7M
Q2 24
$1.2M
$-13.5M
Gross Margin
CTO
CTO
HCAT
HCAT
Q1 26
Q4 25
75.0%
Q3 25
75.4%
52.6%
Q2 25
73.0%
Q1 25
75.2%
Q4 24
74.4%
Q3 24
74.4%
47.5%
Q2 24
71.1%
Operating Margin
CTO
CTO
HCAT
HCAT
Q1 26
175.0%
Q4 25
75.1%
-115.3%
Q3 25
26.6%
-22.9%
Q2 25
-33.7%
-46.0%
Q1 25
22.0%
-25.4%
Q4 24
-20.4%
-22.0%
Q3 24
15.6%
-17.9%
Q2 24
18.8%
-20.8%
Net Margin
CTO
CTO
HCAT
HCAT
Q1 26
15.1%
Q4 25
73.9%
-121.9%
Q3 25
7.7%
-29.1%
Q2 25
-62.2%
-50.8%
Q1 25
6.3%
-29.9%
Q4 24
-42.6%
-26.0%
Q3 24
19.6%
-19.3%
Q2 24
4.1%
-17.8%
EPS (diluted)
CTO
CTO
HCAT
HCAT
Q1 26
$0.13
Q4 25
$0.81
$-1.29
Q3 25
$0.03
$-0.32
Q2 25
$-0.77
$-0.59
Q1 25
$0.01
$-0.35
Q4 24
$-0.69
$-0.33
Q3 24
$0.17
$-0.24
Q2 24
$-0.03
$-0.23

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CTO
CTO
HCAT
HCAT
Cash + ST InvestmentsLiquidity on hand
$8.3M
$95.7M
Total DebtLower is stronger
$153.3M
Stockholders' EquityBook value
$575.4M
$245.8M
Total Assets
$1.3B
$502.6M
Debt / EquityLower = less leverage
0.62×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CTO
CTO
HCAT
HCAT
Q1 26
$8.3M
Q4 25
$6.5M
$95.7M
Q3 25
$9.3M
$91.5M
Q2 25
$8.6M
$97.3M
Q1 25
$8.4M
$342.0M
Q4 24
$9.0M
$392.0M
Q3 24
$8.2M
$387.3M
Q2 24
$4.8M
$308.3M
Total Debt
CTO
CTO
HCAT
HCAT
Q1 26
Q4 25
$616.3M
$153.3M
Q3 25
$604.2M
$153.1M
Q2 25
$605.4M
$153.0M
Q1 25
$602.2M
$382.9M
Q4 24
$519.0M
$382.4M
Q3 24
$526.8M
$345.0M
Q2 24
$482.7M
Stockholders' Equity
CTO
CTO
HCAT
HCAT
Q1 26
$575.4M
Q4 25
$567.3M
$245.8M
Q3 25
$557.3M
$331.9M
Q2 25
$574.1M
$347.5M
Q1 25
$593.9M
$376.8M
Q4 24
$612.8M
$365.2M
Q3 24
$595.8M
$355.0M
Q2 24
$491.8M
$357.0M
Total Assets
CTO
CTO
HCAT
HCAT
Q1 26
$1.3B
Q4 25
$1.3B
$502.6M
Q3 25
$1.2B
$587.1M
Q2 25
$1.2B
$616.2M
Q1 25
$1.2B
$891.5M
Q4 24
$1.2B
$858.9M
Q3 24
$1.2B
$813.0M
Q2 24
$1.0B
$691.7M
Debt / Equity
CTO
CTO
HCAT
HCAT
Q1 26
Q4 25
1.09×
0.62×
Q3 25
1.08×
0.46×
Q2 25
1.05×
0.44×
Q1 25
1.01×
1.02×
Q4 24
0.85×
1.05×
Q3 24
0.88×
0.97×
Q2 24
0.98×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CTO
CTO
HCAT
HCAT
Operating Cash FlowLast quarter
$9.9M
Free Cash FlowOCF − Capex
$9.6M
FCF MarginFCF / Revenue
12.9%
Capex IntensityCapex / Revenue
0.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-697.0K

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CTO
CTO
HCAT
HCAT
Q1 26
Q4 25
$64.6M
$9.9M
Q3 25
$25.5M
$-464.0K
Q2 25
$21.9M
$-9.0M
Q1 25
$10.3M
$280.0K
Q4 24
$59.9M
$-3.5M
Q3 24
$21.2M
$6.2M
Q2 24
$12.9M
$1.6M
Free Cash Flow
CTO
CTO
HCAT
HCAT
Q1 26
Q4 25
$9.6M
Q3 25
$-719.0K
Q2 25
$-9.2M
Q1 25
$-390.0K
Q4 24
$-3.9M
Q3 24
$5.5M
Q2 24
$1.3M
FCF Margin
CTO
CTO
HCAT
HCAT
Q1 26
Q4 25
12.9%
Q3 25
-0.9%
Q2 25
-11.4%
Q1 25
-0.5%
Q4 24
-4.9%
Q3 24
7.2%
Q2 24
1.7%
Capex Intensity
CTO
CTO
HCAT
HCAT
Q1 26
Q4 25
0.4%
Q3 25
0.3%
Q2 25
0.3%
Q1 25
0.8%
Q4 24
0.5%
Q3 24
0.9%
Q2 24
0.4%
Cash Conversion
CTO
CTO
HCAT
HCAT
Q1 26
Q4 25
2.28×
Q3 25
8.75×
Q2 25
Q1 25
4.56×
Q4 24
Q3 24
3.40×
Q2 24
10.89×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CTO
CTO

Segment breakdown not available.

HCAT
HCAT

Recurring Technology$51.9M69%
Professional Services$22.8M31%

Related Comparisons